Reducing the risk of stroke
through efficient and affordable
The Zensor™ device is a complete system solution to allow you to measure and record a patient’s heart rhythm continuously for up 14 days. The extensive beat-by-beat data with optimal trace clarity, can provide critical insight, particularly with paroxysmal and intermittent incidents, to help improve patient outcomes.
Efficient and streamlined workflow
The simplicity of a single device incorporating both ambulatory ECG and event monitoring can help in streamlining the day-to-day workflow. Patient data can be directly uploaded to pre-set and customisable templates to produce time-saving and comprehensive reports, ready for consultation.
Cost-effective AF screening
As a reusable system, the Zensor™ device is associated with substantial savings compared to single-patient use devices. With the combined device and software package, patient screening becomes increasingly cost-effective with each subsequent use.
Compliance and Feedback
The patient-friendly Zensor™ device facilitates high patient compliance. With minimal setup and maintenance required by the patient, all the data you need will be collected and collated for you over a single monitoring period.
Clinician and patient feedback for the Zensor™ device has been overwhelmingly positive – here is a selection of the positive feedback we have received from both clinicians and patients.
Health professional and end-user feedback
- "Very useful for quick diagnosis"
- "Patients have been positive about the experience"
- "State of the art device, which is compact and easy to wear for the patients"
- "Easy to use for clinical staff and patients"
- "A very positive and quick way to be diagnosed"
- "After a day or two I did not notice wearing it"
- "I felt confident using the Zensor™ device"
- "The device was fine to wear, forgot it was on most of the time"
- "It is a good idea to have a device which you can use in real time"
Supporting Zensor™ device
The Zensor™ device has been used to date in hundreds of patients in Europe and the US. At Tallaght University Hospital, Dublin, Ireland, a study was undertaken to identify high risk patients with AF. The device was proven to deliver an effective, convenient and reliable method of diagnosing AF in a high risk population.